LJPC 501

Drug Profile

LJPC 501

Alternative Names: LJPC-501; Synthetic angiotensin II - La Jolla

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
  • Mechanism of Action Angiotensin receptor agonists; Sodium-hydrogen antiporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypotension
  • Discontinued Hepatorenal syndrome

Most Recent Events

  • 27 Feb 2017 La Jolla Pharmaceutical announces intention to submit NDA to the US FDA in second half of 2017
  • 27 Feb 2017 Positive top-line efficacy and adverse events data from the phase III ATHOS-3 trial in Hypotension released by La Jolla Pharmaceutical Company
  • 01 Oct 2016 La Jolla Pharmaceutical completes enrolment in the phase III ATHOS clinical trial for Hypotension in Australia, Belgium, Canada, Finland, France, Germany, New Zealand, Switzerland, the USA and United Kingdom after October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top